Most of the more than 7000 rare diseases described thus far are still orphan

Stephane Demotz, PhD
Founder & CEO

Stephane Demotz is the co-Founder and Chief Executive Officer of Dorphan S.A. He has over twenty years of professional experience gained in academic institutions and the pharmaceutical industry. He has occupied scientist and manager positions in pharmaceutical and biotechnology companies in Switzerland and abroad, where he conducted the preclinical development of numerous compounds in the areas of immunology, inflammation, cancer and rare orphan diseases. He was a co-founder of Edimer Biotech S.A., which developed a drug candidate for the rare and orphan disease X-linked hypohidrotic ectodermal dysplasia. As a member of the Swiss Sanfilippo Foundation since its inception, he co-founded Dorphan S.A. to develop drug candidates for the treatment of rare orphan lysosomal storage diseases. Dr. Demotz holds a PhD in biochemistry and immunology from the University of Lausanne.

Vincent Mutel, PhD
Executive Chairman

Vincent Mutel is a seasoned life science entrepreneur. He is currently co-founder and CEO of Inflamalps S.A., co-founder and chairman of Tauderma S.A. and was co-founder, CEO and vice chairman of Addex Pharmaceuticals Ltd, a company he brought to the public Swiss market, and prior to these assignments was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd.